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ABSTRACT
Purpose: There are several settlements in the Northern and Western Regions of Uganda serving 
refugees from South Sudan and Democratic Republic of Congo (DRC), respectively. Trachoma 
prevalence surveys were conducted in a number of those settlements with the aim of determining 
whether interventions for trachoma are required.
Methods: An evaluation unit (EU) was defined as all refugee settlements in one district. Cross- 
sectional population-based trachoma prevalence survey methodologies designed to adhere to 
World Health Organization recommendations were deployed in 11 EUs to assess prevalence of 
trachomatous inflammation—follicular (TF) in 1–9-year-olds and trachomatous trichiasis (TT) 
unknown to the health system in ≥15-year-olds. Household-level water, sanitation and hygiene 
coverage was also assessed in study populations.
Results: A total of 40,892 people were examined across 11 EUs between 2018 and 2020. The prevalence 
of TF in 1–9-year-olds was <5% in all EUs surveyed. The prevalence of trachomatous trichiasis (TT) 
unknown to the health system in ≥15-year-olds was <0.2% in 5 out of 11 EUs surveyed and ≥0.2% in the 
remaining 6 EUs. A high proportion of households had improved water sources, but a low proportion 
had improved latrines or quickly (within a 30-minute return journey) accessible water sources.
Conclusions: Implementation of the antibiotic, facial cleanliness and environmental improvement 
components of the SAFE strategy is not needed for the purposes of trachoma’s elimination as 
a public health problem in these refugee settlements; however, intervention with TT surgery is 
needed in six EUs. Since instability continues to drive displacement of people from South Sudan 
and DRC into Uganda, there is likely to be a high rate of new arrivals to the settlements over the 
coming years. These populations may therefore have trachoma surveillance needs that are distinct 
from the surrounding non-refugee communities.
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Introduction
Trachoma is the world’s leading infectious cause of 
blindness.1 It can be effectively eliminated as a public health 
problem with the World Health Organization (WHO)- 
recommended SAFE strategy,2,3 which includes: Surgery 
for trichiasis; Antibiotics to treat Chlamydia trachomatis 
infection; and Facial cleanliness and Environmental 
improvement to reduce C. trachomatis transmission.4 
WHO has targeted trachoma for elimination as a public 
health problem globally within this decade in the Neglected 
Tropical Diseases Road Map 2021–2030.5 To achieve this, 
the prevalence of trachomatous inflammation—follicular 
(TF) in children aged 1–9 years must be <5% in all pre-
viously endemic districts at least two years after cessation 
of antibiotic mass drug administration (MDA), the pre-
valence of trachomatous trichiasis (TT) unknown to the 
health system must be less than 0.2% in individuals aged 
≥15 years, and there must be a strategy in place to identify 
and manage incident cases of TT.6 Since 2012, there has 
been a dramatic scale-up of global efforts to determine 
prevalence and initiate interventions in all endemic dis-
tricts in a concerted attempt to reach elimination targets.7 
Validation of elimination of trachoma as a public health 
problem in several countries and the massive reduction in 
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the global population at risk of trachoma are evidence of 
the positive impact of these efforts.8
Uganda has a well-established trachoma elimination 
programme and has made substantial progress towards 
trachoma elimination through implementation of the 
SAFE strategy. Baseline mapping of trachoma in sus-
pected-endemic districts took place between 2006–2014. 
The TF prevalence in 1–9-year-olds was ≥5% in 51 
districts and was 66% in the highest-prevalence district. 
As the results of the 2006–2014 surveys emerged, the 
Uganda Ministry of Health started azithromycin MDA 
in line with WHO guidance; the first treatment rounds 
were delivered in 2007. As interventions progressed, the 
Ministry and partners co-developed a plan to progress 
the trachoma elimination agenda in un-surveyed areas. 
A number of initiatives were started, including trachoma 
rapid assessment (TRA9,10) in areas adjacent to formerly 
endemic districts. Because of the high prevalence of 
trachoma in some parts of South Sudan,11,12 all refugee 
camps hosting refugees from South Sudan were invited 
to be assessed through TRA. Between November 2017 
and February 2018, TRAs were conducted in 29 refugee 
settlements hosting South Sudanese refugees to deter-
mine whether population-based prevalence surveys 
(PBPS) were warranted. PBPS were deemed necessary 
where the proportion of children with TF was more than 
5% in any refugee settlement in which a TRA was con-
ducted. There were also many refugee settlements hous-
ing refugees from the Democratic Republic of the Congo 
(DRC) in the Western Region of Uganda but very few 
data from the resident Ugandan population as the 
region was not suspected to be endemic; because tra-
choma was known to be endemic in districts over the 
border in DRC,13 these settlements were also recom-
mended for PBPS.
The objective of these baseline surveys was to esti-
mate the prevalence of TF in children aged 1–9 years, 
the prevalence of TT in people aged ≥15 years and 
coverage of water, sanitation and hygiene (WASH) 
infrastructure in suspected-trachoma-endemic refugee 




The refugee population of identified districts ranged 
from 5,435–287,801 people. Even though districts at 
either end of this range had refugee populations lesser 
than or greater than, respectively, the template 100,000– 
250,000 population for evaluation units (EUs), to align 
with WHO recommendations for implementation units 
for the SAFE strategy,14 an EU was defined here as all 
refugee settlements within a given district. In some 
cases, that involved a single settlement. In other cases, 
it involved multiple settlements.
The surveys presented in this publication were car-
ried out in two separate series. The first took place in 
2018; the second in 2020 (Table 1). Due to updates to 
recommendations for trachoma prevalence surveys 
between the two series,15,16 different design effects for 
TF17 were used for the two time points.
Both 2018 and 2020 survey series aimed to detect an 
anticipated TF prevalence in 1–9-year-olds of 10% with 
an absolute precision of ± 3% at the 95% confidence level 
in each EU. In all surveys, an inflation factor of 1.2 to 
account for non-response was applied. In both survey 
series, the primary sampling unit (PSU) was a settlement 
block, as defined by UNHCR,18 and the secondary sam-
pling unit (SSU) was the household.
In 2018, there were five EUs in the Northern Region 
and one EU in the Western Region. In the planning for 
the 2018 surveys, a design effect of 2.65 was used. The 
calculated minimum sample size was 1,222 children 
aged 1–9 years per EU in 2018 EUs. Survey teams in 
2018 EUs were expected to be able to recruit 35 house-
holds a day. Based on the mean expected number of 
children per household across all settlements, 24 PSUs 
per EU were visited in the 2018 survey series.
In the 2020 surveys, there was one EU in the 
Northern Region and four EUs in the Western Region. 
A design effect of 3.69 was applied to the target sample 
size when planning the surveys. Survey teams in these 
EUs were expected to be able to recruit 30 households 
a day. The calculated minimum sample size was 1,701 
children aged 1–9 years per EU in three of the 2020 EUs 
(Nyakivaale & Oruchinga, Kyangwali and Kyaka II). 
This meant a total of 30 PSUs per EU were required in 
Nyakivaale & Oruchinga, Kyangwali and Kyaka II to 
reach the required sample size. There were two districts 
in the 2020 survey series with small populations 
(<100,000) and a finite population correction19 was 
applied there to appropriately adjust the sample size. 
In the refugee settlements in Rwamwanja, 1,620 children 
were targeted, for which 30 PSUs were thought to be 
sufficient. In the refugee settlements in Lobule, 1,030 
children were targeted, for which 18 PSUs were selected.
In all EUs, PSUs were selected from a full list of 
blocks in each settlement, provided by UNHCR/OPM. 
PSUs for each settlement were systematically selected 
with probability of selection proportional to their popu-
lation size. Where multiple settlements needed to be 
surveyed in a single EU, the number of PSUs from 
each settlement was proportional to the population of 
each settlement. Households (defined as people living 
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together and sharing meals) were selected using 
a compact segment sampling method. All consenting 
individuals aged ≥1 year who had lived in the respective 
settlements for at least 1 year were eligible for enrol-
ment. Where household members aged 1–9 years were 
absent at the time of the team’s first visit to the house-
hold, one return visit was made at the end of the day to 
increase chances of enrolment.
Standard quality assurance and quality control 
measures20 were implemented throughout each survey.
Study ethics
Relevant authorities were consulted before surveys were 
initiated, including the United Nations High 
Commissioner for Refugees (UNHCR), the Office of 
the Prime Minister (OPM) and the administrative 
authorities of districts hosting the refugees. The Vector 
Control Division Research and Ethics Committee 
deemed the surveys to be programmatic work and there-
fore granted a waiver of approval. Ethical approval for 
Tropical Data to provide support for these surveys was 
granted by the London School of Hygiene & Tropical 
Medicine (16105). Permission for households to be 
enrolled in the surveys was sought from heads of each 
selected household. Informed verbal consent for exam-
ination was sought from each survey participant aged 
≥18 years or, in the case of people aged <18 years, their 
parent or guardian. Additionally, children aged 6– 
17 years were asked to assent to take part. Consent for 
examination was recorded in the Tropical Data app used 
for data collection. Individuals found to have TF were 
treated with two tubes of 1% tetracycline eye ointment 
and instructed to apply twice daily for six weeks, pro-
vided at no cost to recipients. Participants with TT were 
referred to the nearest health facility for appropriate 
management, also provided free of charge to the 
participants.
Clinical and demographic data collection
Fieldwork took place in April 2018–February 2020. The 
SAFE strategy had not been implemented in these set-
tlements before these surveys took place. Before taking 
part in the survey, graders and recorders were required 
to pass internationally standardised training using the 
Tropical Data system.21,22 Data were collected and 
recorded in the field by certified graders and recorders.
All consenting participants ≥1 year were examined 
for clinical signs of trachoma using 2.5× binocular 
loupes. Participants were graded for TT, TF and TI 
using the WHO simplified grading system23,24 and in 
2020 EUs, follicle size guides25 fixed to graders’ thumb-
nails to help maintain standardized diagnosis of TF. In 
the 2018 series of surveys (Table 1), distinction between 
the eyelid (upper or lower) from which any deviated 
eyelashes originated was not recorded. In response to 
recommendations on the definition of TT made during 
the fourth Global Scientific Meeting on trachoma and 
subsequent amendments to the WHO simplified grading 
scheme,24,26 the distinction between upper and lower 
eyelid trichiasis was recorded in surveys which took 
place in 2020 (Table 1). Regardless of from which eyelid 
any in-turned eyelashes arose, participants from both 






settlements Refugee settlements EU ID
Date 




Northern Arua Alizi, Ariwa, Lia, Ocea, Odupu, Ofuwa, Siripi, 
Tika
10617 April 2018 4,423 1 289 4,133 2,257 (55)
Northern Yumbe Bidi Bidi Zone 4; Kululu, Zone 3, Bidibidi Zone 1, 
Bidibidi Zone 2, Bidibidi Zone 5
10618 April 2018 4,305 2 198 4,105 2,292 (56)
Northern Moyo Ibakwe; Itula Zone 1; Morobi, Palorinya 10619 April 2018 3,976 2 244 3,730 2,164 (58)
Northern Adjumani Nyumanzi, Pagirinya, Agojo, Ailo1, Ailo 2, Alele, 
Baratuku, Maji 1, Maji 2 Maji 3, Mungula1 
Mungula 2, mirieyi, leleme
10620 April 2018 3,703 0 206 3,497 2,109 (60)
Northern Lamwo Palabek 10621 May 2018 3,620 0 123 3,497 1,932 (55)
Western Kiryandongo Kiryandongo 10622 May 2018 3,995 0 207 3,788 2,133 (56)
Northern Koboko Lobule 10828 February 2020 2,354 1 200 2,153 1,175 (55)
Western Isingiro Nyakivaale & Oruchinga 10829 February 2020 4,248 2 108 4,138 2,217 (54)
Western Kamwengye Rwamwanja 10830 February 2020 4,303 2 112 4,189 2,288 (55)
Western Kikuube Kyangwali 10831 February 2020 3,831 5 184 3,642 2,119 (58)
Western Kyegegwa Kyaka II 10832 February 2020 4215 6 189 4,020 2,234 (56)




series who were identified with trichiasis were addition-
ally assessed for trachomatous scarring (TS)23 of the 
upper tarsal conjunctiva, were asked questions about 
whether they had previously been offered management 
for their trichiasis and whether they had accepted sur-
gery or epilation. TT was defined according to contem-
porary guidelines at the time of each survey. In the 2018 
survey series, TT was called when at least one eyelash 
(eyelid not specified) was touching the eyeball or there 
was evidence of recent removal of in-turned lashes. In 
the 2020 series, TT was called when at least one eyelash 
from the upper eyelid was touching the eyeball, or there 
was evidence of recent removal of in-turned upper eye-
lid eyelashes. TS status was not considered for either 
definition of TT. Examiners cleaned their hands with 
hand sanitiser in between participants to prevent carry- 
over of pathogens.
Water access, sanitation and hygiene coverage
Global positioning satellite coordinates were recorded at 
each surveyed household. A questionnaire on the proxi-
mity and type of WASH facilities was administered to 
household heads or their nominees. The questionnaire 
was an amended version of the WHO/ United Nations 
Children’s Fund (UNICEF) Joint Monitoring 
Programme (JMP) household questionnaire adapted 
for trachoma surveys.15,21,22 Due to updates to the 
Tropical Data WASH questionnaire made between 
2018 and 2020, questions on handwash facilities differed 
between the 2018 and 2020 survey series. The findings of 
the survey were then summarised using WHO/UNICEF 
JMP definitions of water sources and sanitation 
facilities.27
In the 2018 survey series, the questionnaire required 
data recorders to observe whether there was a handwash 
facility within 10metres of a latrine. Where there was no 
latrine, the question was not asked. In the 2020 survey 
series, recorders were asked to observe whether there 
was a handwash facility on or near the household pre-
mises. In both questionnaires, identified handwash facil-
ities were checked for availability of soap and water.
Data analysis
Unadjusted prevalence estimates, adjusted prevalence 
estimates and confidence intervals of TF and TT 
unknown to the health system in key indicator age 
groups (1–9-year-olds and ≥15-years-olds, respectively) 
were generated using analysis protocols standardised for 
the Global Trachoma Mapping Project and Tropical 
Data.15 Association between TF (dependent variable) 
and age, gender and household-level variables 
(independent variables) was assessed using a mixed- 
effects binomial regression model as described 
elsewhere28,29 with EU and PSU of residence included 
as random-effect variables. The association between TT, 
age and gender was tested using a mixed-effects model 
with PSU of residence included as a random effect vari-
able. For the association between TT, age and gender, 
TT was defined as upper and/or lower lid TT to ensure 
data from all EUs could be included. Model compari-
sons were carried out using likelihood ratio tests, and 
p-values <0.05 were considered significant.
Results
Study population
There were 42,973 people aged ≥1 year enumerated in 11 
EUs. This included 18,480 participants aged ≥15 years 
and 20,589 participants aged 1–9 years. 40,892 (95%) of 
the enumerated individuals were examined. The 
response rate was 98% and 93% among 1–9-year-olds 
and ≥15-year-olds, respectively. The numbers of parti-
cipants enumerated and examined in each EU are shown 
in Table 1.
Clinical signs of disease
A total of 336 children aged 1–9 years were identified 
with TF, and 72 were identified with trachomatous 
inflammation—intense (TI) across all 11 EUs. The 
adjusted EU-level prevalence of TF in 1–9-year-olds 
was <5% in all EUs and ranged from 0.8–3.6%. The 
number of children with active (inflammatory) tra-
choma and the adjusted prevalence of disease in each 
EU is shown in Table 2. Among children aged 1–9 years, 
TF was less common in those aged 7–9 years than 
younger children (odds ratio [OR]: 0.58, 95% confidence 
interval [CI] 0.44–0.77). TF was not associated with any 
other individual- or household-level variables 
(Supplementary Table 1).
The number of adults with TT and the adjusted pre-
valence of TT unknown to the health system is shown in 
Table 3. Disease prevalence in each EU is visualised in 
Figure 1. In the six EUs surveyed in 2018, TT was above 
the WHO elimination threshold of 0.2%; however, the 
eyelid(s) of origin of in-turned eyelash(es) was not 
recorded. In these EUs, 102 cases of TT (eyelid not 
specified) were identified, of which 88 had concurrent 
TT and TS. Of the 102 people with TT, 91 had a least one 
eye with TT for which management had not previously 
been offered, so were categorised as unknown to the 
health system. In the five EUs surveyed in 2020, the 
eyelid of origin of the misdirected lashes was recorded. 
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Teams identified 13 cases of upper-eyelid TT, of which 
12 were unknown to the health system. There were three 
participants in the five EUs surveyed in 2020 with lower- 
eyelid trichiasis, one of whom had no upper-eyelid 
involvement. TT (eyelid and management status not 
specified) was more common in older people (compared 
to the reference age group of 15–34-year-olds, adjusted 
OR [aOR] for 35 − 54-year-olds: 2.9, 95% CI: 1.7 − 4.9; 
for 55 − 74-year-olds: 11.7, 95% CI: 7.1 − 19.4; for ≥75- 
year-olds: 30.7, 95% CI: 16.7 − 56.4; Figure 2; 
Supplementary Table 2) and in females compared to 
males (aOR: 2.5, 95% CI: 1.6–4.0, p < .001; 
Supplementary Table 2).
WASH infrastructure coverage
The household-level water and waste management in 
these refugee settlements varied between EUs. The 
range in EU-level proportion of households with an 
improved drinking water source was 67–100%. 
Notably, in five EUs, 100% of households had access to 
an improved water source, although it took 
approximately half the households in those EUs 
>30 minutes (including waiting time) to get drinking 
water (Table 4). The median proportion of households 
per EU with an improved latrine was 30% (range: 17– 
88%) (Table 4). Handwashing facility access was more 
limited across the study areas (Table 4).
Discussion
The potential risk of re-introduction of ocular 
C. trachomatis infection into treated communities fol-
lowing cross-border migration from the neighbouring 
trachoma-endemic countries of DRC and South Sudan 
warranted surveys of trachoma in refugee populations 
displaced into Uganda. Here, the prevalence of TF in 1– 
9-year-olds was <5% in all 11 EUs studied, suggesting 
antibiotic MDA is not warranted in these populations 
for trachoma elimination purposes. If the prevalence of 
trachoma was high in the surrounding host district 
communities, there may be a risk of seeding of new 
infections into the refugee population. According to 
the Global Trachoma Atlas (www.trachomaatlas.org), 
Table 2. Children aged 1–9 years with active (inflammatory) trachoma in refugee settlements in Uganda, April 2018–February 2020.
Region
District hosting refugee 
settlements
Number of 1–9-year-olds 
examined
Number of 1–9-year-olds 
with TF
Number of 1–9-year-olds 
with TI
Adjusted TF prevalence (%, 
95% CI)
Northern Arua 2,177 32 6 1.44 (0.94─2.13)
Northern Yumbe 2,055 37 5 1.79 (0.84─2.93)
Northern Moyo 1,904 14 4 0.79 (0.32─1.39)
Northern Adjumani 1,865 33 2 1.95 (0.81─3.55)
Northern Lamwo 1,821 30 3 1.80 (0.77─3.13)
Western Kiryandongo 1,905 23 4 1.24 (0.66─1.78)
Northern Koboko 909 14 8 1.29 (0.25─3.01)
Western Isingiro 1,935 72 18 3.56 (1.89─5.40)
Western Kamwengye 1,978 16 1 0.82 (0.36─1.43)
Western Kikuube 1,676 37 13 1.97 (0.92─2.91)
Western Kyegegwa 1,904 28 8 1.29 (0.74─2.01)
Total 20,129 336 72 -
Table 3. Participants aged ≥15 years with trichiasis and adjusted prevalence of trachomatous trichiasis (TT) unknown to the health 




























Adjusted prevalence of 
trichiasis (eyelid not 
specified) unknown to 
the health system (%, 
95% CI)
Adjusted prevalence of 
upper-eyelid trichiasis 
unknown to the health 
system (%, 95% CI)
Northern Arua 1,696 9 9 8 - - 0.35 (0.03–0.89) -
Northern Yumbe 1,749 5 6 6 - - 0.41 (0.05–1.1) -
Northern Moyo 1,651 10 10 10 - - 0.42 (0.18–0.68) -
Northern Adjumani 1,462 22 27 24 - - 0.53 (0.22–0.97) -
Northern Lamwo 1,500 13 16 13 - - 0.51 (0.23–0.91) -
Western Kiryandongo 1,588 29 34 30 - - 1.4 (0.66–2.2) -
Northern Koboko 970 - - - 3 3 - 0.13 (0.00–0.28)
Western Isingiro 1,750 - - - 2 2 - 0.05 (0.00–0.12)
Western Kamwengye 1,659 - - - 1 1 - 0.03 (0.00–0.09)
Western Kikuube 1,503 - - - 5 4 - 0.10 (0.01–0.19)
Western Kyegegwa 1,609 - - - 2 2 - 0.05 (0.00–0.12)
Total 17,137
-: not reported. 
CI: confidence interval; TS: trachomatous scarring.
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Figure 1. Prevalence of (a) trachomatous inflammation—follicular (TF) in 1–9-year-olds, and (b) trachomatous trichiasis (TT) unknown 
to the health system in ≥15-year-olds, in refugee settlements in Uganda, April 2018–February 2020. The definition of an evaluation unit 
in these surveys was all refugee settlements within a given district. Coloured symbols are positioned at the centroid of districts from 
which refugee settlements were sampled. The boundaries and names shown and the designations used on these maps do not imply 
the expression of any opinion whatsoever on the part of the authors, or the institutions with which they are affiliated, concerning the 
legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
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the prevalence of TF in children in the resident Ugandan 
population was <5% at most recent survey in host dis-
tricts in the Northern Region. Other host districts 
(Isingiro, Kamwengye, Kikube, Koboko and Kyegegwa) 
have not recently been surveyed because they are not 
suspected to be endemic for trachoma. The risk of seed-
ing of new infections from surrounding communities 
into refugee settlements is therefore expected to be low.
Prevalence of TT unknown to the health system was 
≥0.2% in six (five Northern, one Western) refugee 
settlement EUs; therefore, active identification and 
management of TT is needed in these areas. 
Assuming 40% of the population are aged ≥15 years, 
we might expect there to be ~2,100 trichiasis cases 
across all these six EUs (calculated using the approach 
suggested by Solomon et al. and in acknowledgement 
of the inherent inaccuracy in such estimates.30) 
Currently, these services are delivered through village 
health teams in each block who are trained as TT case 
finders. When village health teams encounter an indi-
vidual with TT, they are referred to the Ophthalmic 
Clinical Officer at the local health facility, who con-
firms the diagnosis and registers the individual for 
management at annual outreach clinics. There are 
also annual case finding campaigns. The best method 
to deliver these services sustainably may differ from the 
method used to deliver surgical services to the perma-
nently resident communities of host districts and will 
require close collaboration between the Uganda 
Ministry of Health and administrative bodies support-
ing refugees. The requirements for ongoing surveil-
lance of these settlements are also likely to differ from 
those applying to permanently resident populations, 
due to higher rates of in- and out-migration in refugee 
settlements. The reasons for the higher TT prevalence 
in the six EUs with a TT prevalence >0.2% are not 
clear. Because TT takes many years to develop, the 
data collected in these cross-sectional surveys are unli-
kely to be able to capture the complex accumulated risk 
factors from the lifetime of an individual with TT, 
especially because we collected no additional data on 
participants living situation prior to arrival at the set-
tlement. We were also unable to generate hypotheses 
on the reasons for the higher TT prevalence through 
review of routinely available UNHCR data from the 
settlements (data2.unhcr.org/en/country/uga).
Given the high prevalence of trachoma in South 
Sudan12,31 in particular, it is surprising that the pre-
valence of TF among the refugee population was so 
low. This low prevalence has been noted in other 
Figure 2. Proportion of refugee settlement residents in Uganda with trachomatous trichiasis (TT; lid and management status not 
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settlements serving refugees from South Sudan, for 
example in Sudan and in Ethiopia.32,33 A number of 
factors may contribute. First, interactions between 
children and therefore transmission dynamics may 
differ in refugee settlements where there is more 
resident turnover and less familiarity between neigh-
bours. Second, the poorest and most vulnerable 
among society may be simultaneously more likely to 
have trachoma and less likely to leave their original 
country of residence,34 thereby reducing the influx of 
affected individuals into refugee camps. Finally, it is 
notable that the majority of households had good 
access to improved water sources in this study, 
a finding which matches closely with UNHCR mon-
itoring data from some of these settlements (wash. 
unhcr.org/wash-dashboard-for-refugee-settings/). 
There may also be other infrastructure components 
not recorded in these surveys which help people 
maintain facial cleanliness and thereby reduce risk 
of acquiring trachoma. (It should be noted that in 
Sudan, the odds of having TF were 2.6-times higher 
in children living in internally-displaced person 
camps than in children living elsewhere, so the low 
risk noted in this paragraph is not universal.)29
Despite the relatively low prevalence, the age distri-
bution of trachoma in these populations was typical of 
other more heavily trachoma-endemic populations – TF 
was most common in pre-school age children and TT 
was most common in the oldest adults.29,35–37 TT also 
disproportionately affected women38 in these surveys. In 
addition, there was some marginal evidence that TF was 
more common in children living > 30 minutes away 
from a drinking water source (aOR 1.27; 95% CI: 0.98– 
1.64, p = .051) and in children using surface water for 
drinking water (aOR: 1.93; 95% CI: 1.12–3.32, p = .051). 
There is particular room for improvement in the proxi-
mity of water sources to household, the provision of 
improved latrines and the provision of handwash facil-
ities in these settlements which should be rectified, not 
just from the point of view of preventing trachoma.39
We find that refugee settlements in Uganda are not in 
need of antibiotic MDA, facial cleanliness promotion or 
environmental improvement for the purposes of tracho-
ma’s elimination as a public health problem. However, 
due to the mobile nature of displaced populations, this 
situation could change if the population of these settle-
ments’ changes. Therefore, improvements to WASH 
facilities which may overlap with F and E activities 
may still be valuable. The 2021–2030 NTD roadmap 
recommends targeting 100% access to basic WASH 
facilities as part of an integrated and sustainable NTD 
control strategy,5 an approach which has been embraced 
in Uganda’s most recent sustainability plan for NTD 
control, released in February 2021.40 Furthermore, 
active case identification and management of TT is 
needed in six of the EUs. It is likely that refugee settle-
ments may need more regular surveillance than perma-
nently inhabited neighbouring areas. Close 
collaboration between health authorities and partners 
could enable trachoma screening to be integrated with 
routine health provision in refugee settlements. 
Innovative solutions such as these are required to ensure 
that the health of refugees and the surrounding commu-
nities is maintained.
Conclusions
Implementation of the antibiotic, facial cleanliness and 
environmental improvement components of the SAFE 
strategy is not needed for the purposes of trachoma’s 
elimination as a public health problem in these refugee 
settlements; however, intervention with TT surgery is 
needed in six EUs. Since instability continues to drive 
displacement of people from South Sudan and DRC into 
Uganda, there is likely to be a high rate of new arrivals to 
the settlements over the coming years. These popula-
tions may therefore have trachoma surveillance needs 
that are distinct from the surrounding non-refugee 
communities.
Acknowledgments
We thank the participants who took part in the survey. We 
thank the Ministry of Health leadership for their support of 
the trachoma programme.
Disclosure statement
AB and SB are employed by the International Trachoma 
Initiative at The Task Force for Global Health, which 
receives an operating budget and research funds from 
Pfizer Inc., the manufacturers of Zithromax® 
(azithromycin).
EMHE receives salary support from the International 
Trachoma Initiative.
GB works for the Ministry of Health, Kampala Uganda
The other authors have no competing interests
Funding
Core Tropical Data funding was provided by the International 
Trachoma Initiative; Sightsavers; and RTI International 
through the United States Agency for International 
Development (USAID) Act to End NTDs | East program. 
AWS is a staff member of the World Health Organization. 
OPHTHALMIC EPIDEMIOLOGY 9
Disclaimer
The authors alone are responsible for the views expressed in 
this article and they do not necessarily represent the views, 
decisions or policies of the institutions with which they are 
affiliated, USAID or the United States Government.
References
1. Bourne RA, Stevens Ga, White RA, et al. Causes of 
vision loss worldwide, 1990-2010: a systematic 
analysis. Lancet Glob Health. 2013;1(6):e339–49. 
doi:10.1016/S2214-109X(13)70113-X.
2. Hammou J, Obtel M, Razine R, Berraho A, Belmekki M. 
Elimination of trachoma from Morocco: a historical 
review. East Mediterr Heal J. 2020;26(6):713–719. 
doi:10.26719/emhj.19.014.
3. Debrah O, Mensah EO, Senyonjo L, et al. Elimination of 
trachoma as a public health problem in Ghana: provid-
ing evidence through a pre-validation survey. PLoS Negl 
Trop Dis. 2017;11(12):1–15.doi:10.1371/journal. 
pntd.0006099.
4. Francis V, Turner V. Acheiving Community Support for 
Trachoma Control: A Guide for District Health Work 
(WHO/PBL/93.36). Geneva, Switzerland: World Health 
Organization; 1995.
5. World Health Organization. Ending the neglect to attain 
the sustainable development goals: a road map for 
neglected tropical diseases 2021–2030. Geneva, 
Switzerland: World Health Organization; 2020. https:// 
www.who.int/neglected_diseases/Revised-Draft-NTD- 
Roadmap-23Apr2020.pdf?ua=1 .
6. World Health Organization. Validation of Elimination 
of Trachoma as a Public Health Problem (WHO/HTM/ 
NTD/2016.8). Geneva: Switzerland; 2016.
7. Courtright P, Rotondo LA, Macarthur C, et al. 
Strengthening the links between mapping, planning 
and global engagement for disease elimination: lessons 
learnt from trachoma. Br J Ophthalmol. 2018;102 
(10):1324–1327.doi:10.1136/bjophthalmol-2018- 
312476.
8. World Health Organization, Global Alliance for the 
Elimination of Trachoma by 2020. WHO alliance for 
the global elimination of trachoma by 2020: progress 
report, 2019. Wkly Epidemiol Rec. 2020;30(94):349–360.
9. Negrel A-D, Taylor HR, West SK. Guidelines for the 
Rapid Assessment of Trachoma. Geneva: Switzerland; 
2001.
10. Mathew AA, Keeffe JE, Le Mesurier RT, Taylor HR. 
Trachoma in the Pacific Islands: evidence from tra-
choma rapid assessment. Br J Ophthalmol. 2009;93 
(7):866–870. doi:10.1136/bjo.2008.151720.
11. Ngondi J, Ole-Sempele F, Onsarigo A, et al. Blinding 
trachoma in postconflict southern Sudan. PLoS Med. 
2006;3(12):e478.doi:10.1371/journal.pmed.0030478.
12. Edwards T, Smith J, Sturrock HJW, et al. Prevalence 
of trachoma in unity state, South Sudan: results from 
a large-scale population-based survey and potential 
implications for further surveys. PLoS Negl Trop Dis. 
2012;6(4):e1585.doi:10.1371/journal.pntd.0001585.
13. Kilangalanga J, Ndjemba JM, Uvon PA, et al. 
Trachoma in the democratic republic of the congo: 
results of 46 baseline prevalence surveys conducted 
with the global trachoma mapping project. 
Ophthalmic Epidemiol. 2018;25(sup1):192–200. 
doi:10.1080/09286586.2017.1306869.
14. World Health Organization. Report of the 2nd Global 
Scientific Meeting on Trachoma. Geneva: Switzerland; 
August 25-27, 2003.
15. Solomon AW, Pavluck AL, Courtright P, et al. The 
global trachoma mapping project: methodology of a 
34-country population-based study. Ophthalmic 
Epidemiol. 2015;22(3):214–225. doi:10.3109/ 
09286586.2015.1037401.
16. World Health Organization. Design Parameters for 
Population-Based Trachoma Prevalence Survey 
(WHO/HTM/NTD/PCT/2018.07). Geneva: 
Switzerland; 2018.
17. Macleod CK, Bailey RL, Dejene M, et al. Estimating the 
intracluster correlation coefficient for the clinical sign 
“Trachomatous Inflammation—Follicular” in popula-
tion-based trachoma prevalence surveys: results from 
a meta-regression analysis of 261 standardized preinter-
vention surveys carried O. Am J Epidemiol. 2019;00:1–9. 
doi:10.1093/aje/kwz196.
18. The UN Refugee Agency. Camp planning standards 
(planned settlements). UNHCR Emerg Handb. 
2019;183(183): 1–8. https://emergency.unhcr.org/ 
entry/45582/camp-planning-standards-planned- 
settlements 
19. Kirkwood B, Sterne JA. Essential Medical Statistics. 
Oxford, UK: Blackwell Publishing Ltd; 2003.
20. Solomon AW, Willis R, Pavluck AL, et al. Quality 
assurance and quality control in the global trachoma 
mapping project. Am J Trop Med Hyg. 2018;99 
(4):858–863.doi:10.4269/ajtmh.18-0082.
21. Courtright P, MacArthur C, Macleod C, et al. Tropical 
Data: Training System for Trachoma Prevalence Surveys 
(Version 2). London: UK; 2017.
22. Courtright P, MacArthur C, Macleod C, et al. Tropical 
Data: Training System for Trachoma Prevalence Surveys 
(Version 3). London, UK: International Coalition for 
Trachoma Control; 2019.
23. Thylefors B, Dawson CR, Jones BR, West SK, 
Taylor HR. A simple system for the assessment of tra-
choma and its complications. Bull World Health Organ. 
1987;65:477–483.
24. Solomon AW, Kello AB, Bangert M, et al. The simpli-
fied trachoma grading system, amended. Bull World 
Health Organ. 2020;98(10):645–724. doi:10.2471/ 
BLT.19.248708.
25. Solomon AW, Le Mesurier RT, Williams WJ. 
A diagnostic instrument to help field graders eval-
uate active trachoma. Ophthalmic Epidemiol. 
2018;25(5–6):399–402. doi:10.1080/ 
09286586.2018.1500616.
26. World Health Organization. Report of the 4th Global 
Scientific Meeting on Trachoma (WHO/HTM/NTD/ 
PCT/2019.03). Geneva: Switzerland; 2018.
27. World Health Organisation(WHO)/UNICEF. 
Improved and unimproved water sources and sanita-
tion facilities. WHO/UNICEF Joint Monitoring 
Programme(JMP) for Water Supply and Sanitation.
10 G. BAAYENDA ET AL.
28. Alada JJ, Mpyet C, Florea VV, et al. Prevalence of 
trachoma in Kogi State, Nigeria: results of four local 
government area-level surveys from the global tra-
choma mapping project. Ophthalmic Epidemiol. 
2018;25(sup1):33–40. doi:10.1080/ 
09286586.2017.1409359.
29. Elshafie BE, Osman KH, Macleod C, et al. The epide-
miology of trachoma in darfur states and Khartoum 
State, Sudan: results of 32 population-based prevalence 
surveys. Ophthalmic Epidemiol. 2016;23(6): 381–391. 
https://www.tandfonline.com/doi/full/10.1080/ 
09286586.2016.1243718 
30. Solomon AW, Bella AL, Negussu N, Willis R, Taylor H. 
How much trachomatous trichiasis is there? A guide to 
calculating district-level estimates. Community Eye 
Health. 2019;31:S5–S8.
31. Gouda H, Powles J, Barendregt J, Emerson P, Ngondi J, 
Vinetz JM. The burden of Trachoma in South Sudan: 
assessing the health losses from a condition of graded 
severity. PLoS Negl Trop Dis. 2012;6(3):3. doi:10.1371/ 
journal.pntd.0001538.
32. Sanders AM, Abdalla Z, Elshafie BE, et al. Prevalence of 
trachoma within refugee camps serving south sudanese 
refugees in white nile state, sudan: results from 
population-based surveys. PLoS Negl Trop Dis. 2019;13 
(6):1–16.doi:10.1371/journal.pntd.0007491.
33. GelawY,AbatenehA. Blinding trachoma among refu-
gees: complicating social disaster. Asian Pac J Trop 
Biomed. 2015;5(2):124–127. doi:10.1016/s2221- 
1691(15)30155-6.
34. Hull D. Migration, adaptation, and illness: a review. Soc 
Sci Med Part A Med Psychol Med. 1979;13(C):25–36. 
doi:10.1016/0271-7123(79)90005-1.
35. Courtright P, Sheppard J, Schachter J, Said ME, 
Dawson CR. Trachoma and blindness in the Nile 
Delta: current patterns and projections for the 
future in the rural Egyptian population. Br 
J Ophthalmol. 1989;73(7):536–540. doi:10.1136/ 
bjo.73.7.536.
36. Adera TH, Macleod C, Endriyas M, et al. Prevalence 
of and risk factors for Trachoma in Southern 
Nations, Nationalities, and peoples’ region, 
Ethiopia: results of 40 population-based prevalence 
surveys carried out with the global trachoma map-
ping project. Ophthalmic Epidemiol. 2016;23 
(Suppl.1): 1–7. http://www.tandfonline.com/doi/ 
full/10.1080/09286586.2016.1247876 
37. Bero B, Macleod CK, Alemayehu W, et al. Prevalence of 
and risk factors for trachoma in oromia regional state of 
Ethiopia: results of 79 population-based prevalence sur-
veys conducted with the global trachoma mapping 
project. Ophthalmic Epidemiol. 2016;23(6):392–405. 
doi:10.1080/09286586.2016.1243717.
38. Cromwell EA, Courtright P, King , JD, Rotondo LA, 
Ngondi J, Emerson PM. The excess burden of tracho-
matous trichiasis in women: a systematic review and 
meta-analysis. Trans R Soc Trop Med Hyg. 2009;103 
(10):985–992. doi:10.1016/j.trstmh.2009.03.012.
39. Boisson S, Engels D, Gordon BA, et al. Water, 
Sanitation and Hygiene for accelerating and sustaining 
progress on neglected tropical diseases: a new global 
strategy. Int Health. 2017;8(Suppl 1):1–5.doi:10.1093/ 
inthealth/ihv073.Water.
40. Republic of Uganda Ministry of Health. Sustainability 
Plan for Neglected Tropical Diseases Control Programme 
2020-2025. Kampala: Uganda; 2021.
OPHTHALMIC EPIDEMIOLOGY 11
